BioNTech SE: BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

The companies enter a multi-target research collaboration to develop multiple small molecule programs targeting immune modulation in cancer and potentially other disease areas based on targets selected

Related Keywords

Germany ,Australia ,United States ,Canada ,Poland ,United Kingdom ,Warsaw ,L67 ,Sylke Maas ,Natalia Baranowska ,Pawel Przewiezlikowski ,John Fraunces Lifesci ,Ugur Sahin ,Fosun Pharma ,Company Management Board ,Management Board Of The Company ,Neither The Company ,Genentech ,European Parliament ,Pfizer ,Roche Group ,Sa Warsaw Stock Exchange ,Warsaw Stock Exchange ,Chief Executive Officer ,New Technologies ,Private Securities Litigation Reform Act ,Ryvu Therapeutics ,Ryvu Therapeutic ,Quarterly Report ,Management Board ,Biontech ,Ryvu ,Herapeutics ,Winter ,Lobal ,Collaboration ,Evelop ,Ommercialize ,Immuno ,Odulatory ,Mall ,Olecule ,Candidates ,